Citadel Advisors’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History
Bought
Maintained
Sold
Other funds holding RARX
Citadel Advisors's RARX Position: Q2 2020 in Review
Citadel Advisors sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 42,956 shares — an estimated $2.06M sold.
Citadel Advisors first reported a position in RARX in Q3 2017 and held it in 10 quarters. The position peaked at $37.2M in Q4 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.
- Citadel Advisors reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
- Citadel Advisors sold 42,956 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $2.06M.
- Citadel Advisors first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 10 quarters.
- Citadel Advisors's Ra Pharmaceuticals, Inc. Common Stock position peaked at $37.2M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.
Based on Citadel Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.